Colorectal Cancer Prevention Hospital Universitário São Paulo University

Similar documents
Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc.

FIT Overview. Objectives 6/23/2014

ColonCancerCheck & Regional Updates. Cheryl Shoemaker RN, BScN, CON(C) March 19, 2014

Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial

EVALUATION OF QUANTITATIVE DETECTION OF FECAL HUMAN HAEMOGLOBIN FOR COLORECTAL CANCER SCREENING

Colorectal Cancer Screening

COLORECTAL CANCER SCREENING &THE FECAL IMMUNOCHEMICAL TEST (FIT) MATHEW ESTEY, PHD, FCACB CLINICAL CHEMIST

Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients

FREQUENTLY ASKED QUESTIONS

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

TPMG experience in improving colorectal cancer screening rates

Improving Access to Endoscopy at Safety-Net Hospitals. Lukejohn W. Day MD Assistant Professor of Medicine

Challenges for Colorectal Cancer Screening

T. Rubeca 1, S. Rapi 2, M. Confortini 1, M. Brogioni 2, G. Grazzini 1, M. Zappa 1, D. Puliti 1, G. Castiglione 1, S. Ciatto 1

CRC screening from the viewpoint of its clients and patients results of survey

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?

Czech CRC screening program at the point of switch to the population based design

A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test

Practical challenges in establishing and running the Czech national colorectal cancer screening programme

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE

The choice of methods for Colorectal Cancer Screening; The Dutch experience

Be it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE

Journal of Clinical Laboratory Instruments and Reagents, Vol. 34, No. 3 (June, 2011) Supplement

The Dutch bowel cancer screening program Relevant lessions for Ontario

Evaluation of a desk top instrument for the automated development and immunochemical quantifi cation of fecal occult blood

Screening for Colorectal Cancer: Se0ng it up and making it work. Julie8a Patnick 4 December 2014

Colon Cancer Screening. A Provider Opinion Survey

Colorectal cancer screening

Therapeutic Apheresis in South America

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.

Early detection and screening for colorectal neoplasia

FECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

Combination of Sigmoidoscopy and a Fecal Immunochemical Test to Detect Proximal Colon Neoplasia

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

Measuring performance and quality indicators of CRC screening

Implementing of Population-based FOBT Screening

Supplementary Appendix

Fecal immunochemical testing results and characteristics of colonic lesions

Comparison of FIT performance in screening programs. Carlo Senore

Cost-effectiveness of colonoscopy in screening for colorectal cancer Sonnenberg A, Delco F, Inadomi J M

THE NEW ZEALAND MEDICAL JOURNAL

Screening & Surveillance Guidelines

Page 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!

05/07/2018. Organisation. The English screening programme what is happening? Organisation. Bowel cancer screening in the UK is:

Citation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy

Dr Alasdair Patrick. Dr Nagham Al-Mozany. 9:45-10:10 Where Are We Up To With Bowel Cancer Screening?

(Bowel) Cancer Screening an update. Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot

ColonCancerCheck Program Report

Reflections on the EUnetHTA CRC screening full Core Model pilot 1

CLINICAL SCIENCE ASSESSING SCREENING PRACTICES AMONG HEALTH CARE WORKERS AT A TERTIARY-CARE HOSPITAL IN SAO PAULO, BRAZIL

Colorectal cancer screening in England

National Colonoscopy Study (NCS) Screening Colonoscopy versus Annual Fecal Occult Blood Test NCT

Updates in Colorectal Cancer Screening & Prevention

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2

«Colorectal cancer screening in the regions of the Russian Federation: Stanislav Konovalov Leading expert in HTSA Plus program

Emerging Interventions in Endoscopy. Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests

Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds. Carlo SENORE

North West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist

Primary care at the forefront of colorectal cancer screening

Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening

Colorectal Cancer Screening in Canada: ENVIRONMENTAL SCAN

WEO CRC SC Meeting. Vienna, Austria October 14, 2016

Henrique Prata Director General

Colon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4

Colorectal Cancer Screening and Risk Assessment Workflow. Documentation Guide for Health Center NextGen Users

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Dr Alasdair Patrick Gastroenterologist

Developing Systems to Increase Colorectal Cancer Screening at Health Centers

Grupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market. September 28th, 2012

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)

Blood Based Screening

Rx Only. Detecting Cancer In Blood.

Colorectal Cancer Screening in Canada MONITORING & EVALUATION OF QUALITY INDICATORS RESULTS REPORT

Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci. Colon polyps. Colorectal cancer

Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multicentre

Positive Results on Fecal Blood Tests

Bowel cancer screening and prevention

Page 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.

Course Program. São Paulo, BRAZIL N OV E MB E R 9-1 0, Ataxias and Spastic Paraplegias: From Molecular Biology to Bedside and Treatment

Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods Yamamoto M, Nakama H

Sarvenaz Moosavi, 1 Robert Enns, 1 Laura Gentile, 2 Lovedeep Gondara, 2 Colleen McGahan, 2 and Jennifer Telford Introduction

Pathology in Slovenian CRC screening programme:

Interview with Prof. Guido Costamagna

Guidelines for Breast, Cervical and Colorectal Cancer Screening

The burden of Colorectal Cancer in Asia. Dr Saunthari Somasundaram

Guidance on Implementing FIT-based Screening Programs. June 29th, :00pm ET

Increasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program

Neoplastic Colon Polyps. Joyce Au SUNY Downstate Grand Rounds, October 18, 2012

Challenges in the implementation of National CRC screening programme Turkish experience. Prof.Nurdan Tozun /Turkey

Friday, 23 October 2015: 10:15 12:00 * * * * *

COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.

Implementation of Faecal Immunochemical Testing as the screening test for Bowel Screening. Programme in Wales

Improving Compliance with Fecal Occult Blood Tests, a Colorectal Cancer Screening Tool

LIPPINCOTT WILLIAMS AND WILKINS

Colorectal Cancer & Screening 1 st Men s Health Conference

Transcription:

Colorectal Cancer Prevention Hospital Universitário São Paulo University GENERAL STRATEGY AND RESULTS Dr Luis Masúo Maruta Dr. Marcelo Rodrigues Borba

Hospital Universitário São Paulo University Hospital Universitário (HU) is one of 82 units that compose São Paulo University with 90.000 students and 21.000 employees

Hospital Universitário São Paulo University Secondary Care Hospital Butantã district s population (2010) : 428.217 USP Staff and Students

Colorectal Cancer Prevention Target Population Employees and Faculty of São Paulo University (USP) from 50 to 75 years of age Estimated number: 7500 people Butantã district s population (50-75 age ) that comes to hospital s ambulatory for cancer prevention (spontaneus approach - without active campaign)

Colorectal Cancer Prevention Project design (pilot study) Employees of USP Receive anual convocation USP Healthy Service Faculty of USP Invitation by campaign Endoscopy Service Nurse coord and Program coord Butantã district population Spontaneus approach HU s Ambulatory Request FIT to LAB

Invitation by Campagn: USP network USP web USP news USP radio http://www5.usp.br/40544/hospitaluniversitario-promove-campanhade-prevencao-do-cancer-colorretal/

Colorectal Cancer Prevention Hospital Universitário team Endoscopy Service - 4 Endoscopists + Nurse coordinator Surgery Department + 5 surgeons Pathology Department USP Employees Healthy Service (SESMT) HU S Lab Total : 15 doctors, 3 nurses, 1 secretary and 7 technicians

Colorectal Cancer Prevention Project support - Eiken Co Jp Polymedco Inc USA- Hemagen BR - kit FIT and OC sensor - Tokyo Medical and Dental University Japan - Fuji Film Co Jp GastroCom Ltda LaborMed Ltda - Clinicas Las Condes Chile: trainning course - Dr. Francisco Lopez (trainning for 3 doctors, 1 nurse and 1 Lab technician on april and august 2013)

Colorectal Cancer Prevention Multicentric Project - Hospital Universitário da USP (2013) - Dr. Marcelo R. Borba - Dr. Luis M. Maruta - Fugast Rio Grande do Sul (2013) - Dr. Claudio Rolim Teixeira - Hospital A.C. Camargo SP (2013) - Dr. Samuel Aguiar Jr. - Santa Fé Medical Center - Arapiraca city Alagoas State(2015) - Dr. Herbeth Toledo - Hospital das Clinicas SP (2015) Dr. Ulisses Ribeiro Dr. José Eluf Neto

Colorectal Cancer Prevention Fecal Occult Blood Test Imunological (FIT) Eiken FOBT i Kit - Imunological specific for human hemoglobin Qualitative 2013-2014 50 ng/ml hb Quantitative 2015~ 50-200 ng/ml (adjustable) We kept quantitative cut value to 50ng/ml hb during pilot study. Eiken Co - Jp Polymedco Inc USA Hemagen do Brasil Ltda

Sampling Bottle Sample cup part Filter Buffer 2mL Spiral groove Scraper Sampling quantity 10 mg

Quantitative test OC-SENSOR-DIANA Set reagent Set samples

The advantages of FIT Colorectal screening 1.With its high specificity, dietary restriction is not necessary. 2.With its low cost, and endoscopy examination performed only on the positive examinees, FIT can help to reduce medical expenses. 3.FIT has been demonstrated not only with its detection on an early stage colorectal cancer, but also with its reduction of mortality rate

Tokyo TMDU meeting - march 2015 preliminary results presentation

Cases of FIT from Dec, 10 2013 to June 7th, 2017 A- Number of FITs: 5732 FITs (Atendees: 3869) B- Positive FIT: 289(5,04%) (C/A)= 289/5732 50ng/ml Hg D- Colonoscopies performed in FIT+: 192 (66,4%)=192/289 Scheduled (waiting for colonoscopy) : 47(16.2%)=47/289 Co-morbidity or refused colonoscopy : 50(17,6%) = 50/289

Cases of FIT(+) from Dec, 10 2013 to June 7th, 2017 Colonoscopies performed in FIT+: 192 (66,4%)=192/289 - Normal or benign disease: 72(37,50%) (72/192) - Adenomas(low grade dysplasia/serrated): 105(54,68%) (105/192) - Cancer : 15(7,81%) (15/192) High grade dysplasia: 8(endoscopic treatment) (4,16%) advanced cancer: 7(surgical treatment) (3,64%)

Multicentric Cases of FIT from Dec, 10 2013 to June 7th, 2017 Arapiraca: Santa Fé Medical Centar Resp. Dr. Herbeth Toledo Number of FOBTs: 900 Positivity : 27-3% 100ng/ml Hg HU(5,04%) Colonoscopy - 27 Normal - 16-61,5% HU(37,50%) Low grade dysplasia adenoma 4 (14,8%) High grade dysplasia adenoma 4 (14,8%) HU(8,81%) Hyperplastic polip - 3 (11,1%)

ANNUAL FIT Methodology of screening of colorectal cancer with FIT. Screening Sensitivity Sensitivity of each FIT. Program Sensitivity Sensitivity of repeated tests Increased sensitivity of the program by continuous examination in spite of the low sensitivity of test

Critical analysis - FIT by year from Dec, 10 2013 to June 7th, 2017 Attendees: 3869 patients Number of FITs: 5732 Total FITs 2013-14 2128 4500 CASES OF FIT 2015 1681 3500 2016 1345 2017 578 TOTAL 5732 2500 1500 500 2128 1681 1345 578-500 2013-14 2015 2016 2017

Critical analysis: Cases of repeated FITs (after 1 year or more) CASES OF REPEATED FITS 4500 4000 3869 100% (3869) 3500 3000 2500 2000 1500 1000 500 878 672 313 20,03% (775) 0 1st FITs 2nd FITs 3rd FITs 4th FITs Screening atendees CRC Prevention Atendees (estimated)

Critical analysis Screening was sucessful (highlights) FIT sensitivity (5,04% 50ng/ml Hg) can be used as a index for future programs The use of FIT for asymptomatic patients became routine in HU s medical practice Colorectal Cancer Program points to improve Continuous effort to mobilizing individuals Individuals should be fully aware of procedures to avoid colonoscopy s rejection after FIT +

Thank you luismaruta@terra.com.br